MEK Inhibitor Synthesis via Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an ongoing need for compounds that inhibit MEK for the treatment of cancer, as the MEK-ERK signal transduction pathway is frequently upregulated in human tumors, and existing strategies for targeting this pathway are not fully effective.
Innovation Solution
A process for making compounds of formula I, which involves contacting a compound of formula IIa-1 with a compound of formula II-1, where X and R5 are defined, and R10 is F, Br, Cl, or —OSO2—CF3, to produce compounds that inhibit MEK kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are synthesized to inhibit MEK kinase activity for cancer treatment, then therapeutic effectiveness is improved, but the complexity of the synthesis process increases
Solution Approach 1:
The synthesis process is divided into multiple discrete steps with clearly defined intermediates (formula IIa-1, formula II-1, formula I). Each step targets a specific transformation, allowing for better control and optimization of individual reactions while maintaining the overall complexity manageable through systematic progression.
Solution Approach 2:
The patent specifies precise structural parameters for the compounds (substituents R1-R9, groups X, R10, R11) and their variations. By defining specific chemical parameters and their ranges, the invention enables systematic optimization of MEK inhibition effectiveness while providing a framework for managing synthesis complexity through parameter control.
2Reliability
If specific substituent groups are introduced to enhance MEK inhibition, then compound efficacy is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent introduces specific substituent groups (R1-R9, X, R10, R11) at defined positions on the molecular structure to enhance MEK inhibition. Each substituent serves a specific functional purpose, allowing optimization of local molecular properties to achieve global therapeutic effectiveness while maintaining manageable manufacturing precision through standardized substitution patterns.
Data Source
AI summary
Disclosed herein is a process of making a compound of formula IThe compound of formula I is an inhibitor of MEK and thus can be used to treat cancer.